Skip to main content

Advertisement

Table 3 Response in patients with AML-MRC treated with azacitidine or CCR

From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

All patients with AML-MRC (N = 262)
  AZA (n = 129) CCR (n = 133)
n (%)
Overall Response Rate (CR + CRi) 32 (24.8) 23 (17.3)
CR 25 (19.4) 20 (15.0)
CRi 7 (5.4) 3 (2.3)
Partial remission 1 (0.8) 2 (1.5)
Stable disease 46 (35.7) 38 (28.6)
Progressive disease 11 (8.5) 16 (12.0)
  AML-MRC patients with Intermediate-risk cytogenetics AML-MRC patients with Poor-risk cytogenetics
AZA (n = 63) CCR (n = 61) AZA (n = 66) CCR (n = 72)
n (%)
Overall Response Rate (CR + CRi) 21 (33.3) 15 (24.6) 11 (16.7) 8 (11.1)
CR 18 (28.6) 13 (21.3) 7 (10.6) 7 (9.7)
CRi 3 (4.8) 2 (3.3) 4 (6.1) 1 (1.4)
Partial remission 1 (1.6) 1 (1.6) 0 1 (1.4)
Stable disease 25 (39.7) 18 (29.5) 21 (31.8) 20 (27.8)
Progressive disease 6 (9.5) 5 (8.2) 5 (7.6) 11 (15.3)
  AML-MRC patients ages 65–74 years AML-MRC patients ages ≥ 75 years
AZA (n = 52) CCR (n = 64) AZA (n = 77) CCR (n = 69)
n (%)
Overall Response Rate (CR + CRi) 15 (28.8) 16 (25.0) 17 (22.1) 7 (10.1)
CR 11 (21.2) 14 (21.9) 14 (18.2) 6 (8.7)
CRi 4 (7.7) 2 (3.1) 3 (3.9) 1 (1.4)
Partial remission 0 2 (3.1) 1 (1.3) 0
Stable disease 20 (38.5) 24 (37.5) 26 (33.8) 14 (20.3)
Progressive disease 5 (9.6) 6 (9.4) 6 (7.8) 10 (14.5)
  1. AML-MRC, AML with myelodysplasia-related changes; AZA, azacitidine; CCR, conventional care regimens; CR, complete remission; CRi, CR with incomplete blood count recovery